← Eichor
Study identifier: NCT06041334 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Evaluation of muLtimodal and Non-invasive SPINa Bifida Neurovessels During Prospective Follow-up

Condition: Spina Bifida  ·  Sponsor: Rennes University Hospital

PhaseNA
Planned participants50
Who can joinAll sexes, 6 Years to no upper limit
Healthy volunteersNo

About this study

The aim of the study is to investigate known urinary biomarkers in order to determine whether they can be predictive of a risk of damage to the upper urinary tract and therefore the kidneys in patients with spina bifida. The risk of damage to the upper urinary tract can be calculated using the Galloway score, based on the results of the urodynamic study and retrograde urethrocystography, which all patients with spina bifida have regularly. The urinary biomarkers studied TIMP-2 (Tissue inhibitor of metalloproteinases 2) and MMP-2 (matrix metalloproteinase-2) are potentially associated with renal degradation, but this has not yet been demonstrated. Volunteers to take part in the study will have their biomarkers measured at the time of their urodynamic assessment.

This description comes directly from the study's public registry record.

Talk to the study team

LOÏC JACOB  ·  0299282555  ·  loic.jacob@chu-rennes.fr

Always discuss trial participation with your own doctor first.

Locations (1)

Rennes University HospitalRennes, CHU de Rennes, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06041334